Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses the promising results of DB-OTO in the CHORD trial for children with otoferlin-related hearing loss.

Dr. Hernan Bazan, CEO of South Rampart Pharma, discusses his company’s current pipeline.

HEOR scientists in the pharma industry must balance methodologic rigor with commercial expectations and timelines.

The data analytics company based its new product on simple spreadsheet technology.

The latest news for pharma industry insiders.

The approval of neffy marks the first major advancement in epinephrine delivery for patients over four years of age in more than 35 years.

Joint venture is expected to leverage Astellas' expertise in cell therapy R&D and Yaskawa’s robotics technology to enhance accuracy, reproducibility, and efficiency in cell manufacturing.

The six key design trends of 2025 redefine how healthcare brands can inspire trust and build lasting connections with their audiences.

The latest news for pharma industry insiders.

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, describes how his company's recent partnership with Pfizer is impacting drug access.

The acquisition is expected to enhance Jazz's oncology portfolio by adding dordaviprone, a novel small molecule therapy in development for H3 K27M-mutant diffuse glioma.

Submission is supported by positive results from the Phase III REGENCY trial, which demonstrated that nearly half of patients with lupus nephritis who received Gazyva/Gazyvaro plus standard therapy achieved a complete renal response.

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, explores ways that digital health platforms can assist pharma companies seeking to maintain accessibility and manage cost pressures.

Dr. Hernan Bazan, CEO of South Rampart Pharma, discusses his company’s current pipeline.

In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer for Pleio, explores what kind of role regulatory agencies should play in the battle against misinformation.

The latest news for pharma industry insiders.

New indication for Tevimbra in combination with platinum-containing chemotherapy as a first-line treatment addresses an unmet need for adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1.

Stoboclo, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Osenvelt, a biosimilar to Xgeva, is indicated for preventing skeletal-related events in patients with multiple myeloma and bone metastases from solid tumors.

Aliya Omer, VP, US franchise head, breast cancer, AstraZeneca, discusses how results of the trial compare with other treatments for gBRCAm HER2-negative high-risk early breast cancer.

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, explores how tariffs could affect the availability and accessibility of specific medications, particularly for patients relying on direct-to-patient telehealth.

In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer for Pleio, discusses why pharma increasingly turning to peer-to-patient platforms to educate patients, as well as relationships with trusted patient communities and pharmacies.

The latest news for pharma industry insiders.

In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, obstruction, and asthma exacerbations compared to placebo.

Under terms of the deal, Gubra will receive an initial $350 million payment and could earn up to $1.875 billion more in development and sales milestones for the potential weight loss drug.